ARS Pharmaceuticals, Inc. (SPRY) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ARS Pharmaceuticals, Inc.'s filing signal turned positive.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of neffy, a needle-free intranasal delivery system for epinephrine, designed to treat Type I allergic reactions, including anaphylaxis. neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, offering a novel delivery method for a critical emergency treatment. The company targets a significant unmet need, as approximately 40 million people in the U.S. experience Type I allergic reactions, with a substantial portion of those at risk for anaphylaxis. ARS Pharma has established a direct sales force and a co-promotion partnership in the U.S., alongside global collaborations for international market access. The company is also exploring additional indications for neffy, such as chronic urticaria.

Revenue is driven by net product sales of neffy in the United States and collaboration revenues from upfront payments, milestone achievements, royalties, and supply agreements with international partners.